Tricyclic antidepressant

Tricyclic antidepressants (TCAs) are a class of medications primarily used in the treatment of depression. Named for their three-ring chemical structure, TCAs are among the oldest antidepressants in medical use but have been largely supplanted by newer drugs with fewer side effects.

Imipramine

Pharmacology

TCAs work by inhibiting the reuptake of certain neurotransmitters — specifically serotonin and norepinephrine — in the brain, thereby increasing their availability and enhancing neurotransmission. Some TCAs also have activity against other neurotransmitter receptors, such as acetylcholine and histamine, which contribute to their side effect profiles.

Uses

• While TCAs are most commonly used in the treatment of major depressive disorder, they are also effective in a number of other conditions:
• Anxiety Disorders: Certain TCAs, like imipramine, are used in the treatment of panic disorder and generalized anxiety disorder.
• Chronic Pain: Amitriptyline and nortriptyline, among other TCAs, are frequently used in the management of neuropathic pain and fibromyalgia.
• Insomnia: Due to their sedative effects, some TCAs are used for the short-term treatment of insomnia.
• Enuresis: Imipramine has been used for nocturnal enuresis (bedwetting) in children, although it is not a first-line treatment due to potential side effects.

Side Effects and Overdose

TCAs have a wide range of side effects, largely due to their action on various neurotransmitter systems. These include dry mouth, blurred vision, constipation, urinary retention, dizziness, and weight gain. Additionally, TCAs can cause cardiac arrhythmias and are potentially lethal in overdose.

Interactions

TCAs can interact with many other medications, leading to increased side effects or reduced effectiveness. Examples include other antidepressants, certain antipsychotics, and certain cardiovascular drugs. Patients on TCAs should avoid alcohol due to the risk of enhanced sedation and potential for overdose.

Conclusion

Although TCAs are effective in treating depression and other conditions, their use has declined due to the advent of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), which generally have fewer side effects and are safer in overdose.

See Also

• Antidepressant
• Depression
• Anxiety disorder
• Neuropathic pain

References

<references>

• Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, Dickens C, Ferrier IN, Geddes J, Gilbody S, Haddad PM, Katona C, Lewis G, Malizia A, McAllister-Williams RH, Ramchandani P, Scott J, Taylor D, Uher R (2015). *Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 29 (5): 459–525.
• Hirsch M, Birnbaum RJ. (2012). Tricyclic and Tetracyclic Drugs. In: Tasman A, Kay J, Lieberman JA, First MB, Maj M (eds). Psychiatry. Wiley.
• Sansone RA, Sansone LA. (2012). Tricyclic Antidepressants and Fibromyalgia: What is the Evidence? Innovations in Clinical Neuroscience. 9 (4): 10–14.

Tricyclic antidepressant Resources
Latest articles Most recent articles Ongoing trials	Wikipedia